Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


MiMedx Group, Inc. (Nasdaq: MDXG) (MIMEDX or the Company), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that Timothy R. Wright, Chief Executive Officer, and Rohit Kashyap, Ph.D., Chief Commercial Officer, will present at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29 to December 2, 2021.


GlobeNewswire Inc | Nov 22, 2021 08:00AM EST

November 22, 2021

MARIETTA, Ga., Nov. 22, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (MIMEDX or the Company), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that Timothy R. Wright, Chief Executive Officer, and Rohit Kashyap, Ph.D., Chief Commercial Officer, will present at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29 to December 2, 2021.

Managements presentation will be available to view on-demand beginning Monday, November 22 at 10:00 AM ET. The webcast will be available on the Events page of the Investors section of the Companys website at www.mimedx.com. A replay will be available on the Companys website following the event.

Institutional investors interested in meeting with management may contact their Piper Sandler representative.

About MIMEDXMIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a base business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.MIMEDX.com.

Contacts:InvestorsJack Howarth404-360-5681jhowarth@mimedx.com

Corporate CommunicationsHilary Dixon404-323-4779hdixon@mimedx.com







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC